

From: Alfred Decker <pharma@smiconferences.co.uk>

To: Kester, Tonykester@aging.sc.gov

Date: 9/20/2016 10:41:39 AM

Subject: New updates on CARB-X and an exclusive interview with BARDA | Superbugs USA

"The Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, or CARB-X, represents one of the world's largest public-private partnerships focused on the preclinical discovery and development of new antimicrobial products" - BARDA INTERVIEW

Introducing CARB-X

Hear from those accelerating global innovation to address antibacterial resistance at Superbugs USA

EVENT NEWS:

- Recent Attendees: Motif BioSciences, JSC R-PHARMVenaticus AB, NeoSome Life Sciences
- Event Spotlight: Hear critical updates on national strategy for CARB from **NIH** and **BARDA**
- **New Q&A:** Check out the new interview released today from Branch Chief, Antibacterial Program, BARDA - Dr Christopher Houchens
[Read it here](#)

CARB-X is a new global public-private partnership that will invest more than **US\$350 million** in the next 5 years to accelerate the progression of a diverse portfolio of innovative antibacterial products into clinical trials.*

The Biomedical Advanced Research and Development Authority (**BARDA**) and the National Institute of Allergy and Infectious Diseases (**NIAID**) will join the Wellcome Trust and the AMR Centre in joint oversight of the project.

Hear more from both the NIAD and BARDA at [Superbugs & Superdrugs USA](#) when it arrives to New Jersey on **November 14th & 15th**.

Dr Rosmarie Aurigemma, Chief, Biodefense Drug Development Section from **NIAID, NIH**, will provide an exclusive update on the NIAID National Strategy for CARB and present key findings of the first year

SMi Presents...

SUPERBUGS & SUPERDRUGS USA

November
14th & 15th 2016
Renaissance Woodbridge
Hotel, New Jersey, USA

Sponsored by:
Noigel
Polyphor

**\$200 saving ends
30th Sept**

Register online at:
www.superbugs-usa.com

Sponsorship opportunities:
Contact Alia Malick
+44 (0)20 7827 6168
amalick@smi-online.co.uk

Delegate enquiries:
Contact Matthew Apps
+44 (0)20 7827 6093

from the new initiative.

With a focus on end-to-end support of antibacterial product development, the **BARDA** address will discuss key topics surrounding **repopulating** the antibiotic pipeline, utilizing **PPP's** to stimulate clinical development, non-traditional antibacterials and BARDA's efforts to address objectives in the **US National Action Plan for CARB**.

Other highlights will include an opening address by **PAHO/WHO**, an exclusive keynote from John Rex at **AstraZeneca**, big pharma updates on **clinical progress**, and a focus on **novel therapeutic approaches**.

This is just a quick summary of what to expect at Superbugs & Superdrugs USA. Check out a detailed conference agenda and the full speaker line-up at www.superbugs-usa.com

mapps@smi-online.co.uk

DOWNLOAD BROCHURE

*Source: <http://www.nature.com/nrd/journal/v15/n9/full/nrd.2016.155.html>

You are registered as: kester@aging.sc.gov Your Unique Reference Number: 92804565
To update your contact preferences please go to <http://www.smi-online.co.uk/update-preferences>